Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial

Authors :: Julien Hadoux
Hu Mimi I
Brose Marcia S.
Elena Garralda
Christine Spitzweg
Noemi Reguart
Cao Christine Do
Forster Martin D.
Teresa Alonso-Gordoa
Teresa Barata
Astrid Scalori
Alena Zalutskaya
Peter Trask
Vivek Subbiah
Source :: Endocrine Abstracts.
Publication Year :: 2022
Publisher :: Bioscientifica, 2022.

Full Text Access

Tools